Hikma Pharmaceuticals (Hikma Pharmaceuticals) Additional Paid-In Capital : $282 Mil(As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Additional Paid-In Capital?

Hikma Pharmaceuticals's quarterly additional paid-in capital increased from Dec. 2022 ($282 Mil) to Jun. 2023 ($284 Mil) but then stayed the same from Jun. 2023 ($284 Mil) to Dec. 2023 ($282 Mil).

Hikma Pharmaceuticals's annual additional paid-in capital stayed the same from Dec. 2021 ($282 Mil) to Dec. 2022 ($282 Mil) and stayed the same from Dec. 2022 ($282 Mil) to Dec. 2023 ($282 Mil).

Hikma Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Hikma Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Additional Paid-In Capital Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

282.00

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															282.00	282.00	282.00	284.00	282.00

Hikma Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Hikma Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals (Hikma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HIKl:UK HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.